Trading is expected to resume today for Pacific Edge shares after they were placed in a trading halt on Friday.
A statement to the market on Friday said the cancer diagnostics company became aware on Thursday night of the inclusion of Cxbladder CPT codes in a draft proposal for a different approach to determine which cancer biomarker tests were eligible for reimbursement by Novitas.
Pacific Edge would provide its shareholders with further clarification of the implications for the company once it had received advice from its US legal team and other advisers prior to lifting the trading halt.
